Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.36 |
| ▸ | RXRB | P28702 | 1/20 | 0.36 |
| ▸ | RXRG | P48443 | 1/20 | 0.36 |
| ▸ | CYP4F2 | P78329 | 4/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 4/20 | 0.32 |
| ▸ | RET | P07949 | 2/20 | 0.31 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5377785 | 0.83 | ATM (0.36) | RXRARXRBRXRG | |
| SCHEMBL5378368 | 0.81 | CMKLR1 (0.37) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL5648303 | 0.80 | RXRA (0.32) | RXRARXRBRXRGCD274 | |
| SCHEMBL9904375 | 0.80 | CYP4F2 (0.38) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL30182911 | 0.78 | MAPT (0.38) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL17801039 | 0.77 | HCAR3 (0.43) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL5372718 | 0.76 | DNMT3A (0.42) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL22160453 | 0.76 | CYP4F2 (0.39) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL30950223 | 0.76 | CYP4F2 (0.39) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL20030949 | 0.76 | RXRA (0.36) | RXRARXRBRXRGCYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2065383-A1 | Indazole compounds and methods of use thereof as protein kinase inhibitors | Signal Pharmaceuticals, Inc. (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20090099178-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF | BHAGWAT SHRIPAD S | 2009-04-16 | — | — | US | disclosed |
| US-7220771-B2 | Methods of using indazole derivatives as JNK inhibitors | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-22 | — | — | US | disclosed |
| US-7211594-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-01 | — | — | US | disclosed |
| US-7208513-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-04-24 | — | — | US | disclosed |
| US-20070060616-A1 | Methods for treating, preventing and managing chronic lymphocytic leukemia with indazole compounds | SIGNAL PHARMACEUTICALS, LLC | 2007-03-15 | — | — | US | disclosed |
| EP-1692128-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF AS PROTEIN KINASE INHIBITORS | Signal Pharmaceuticals LLC (US) | 2006-08-23 | — | — | EP | disclosed |
| EP-1618093-A2 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | Signal Pharmaceuticals LLC (US) | 2006-01-25 | — | — | EP | disclosed |
| US-20060004043-A1 | Indazole compounds and methods of use thereof | BHAGWAT SHRIPAD S | 2006-01-05 | — | — | US | disclosed |
| WO-2005051942-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF AS PROTEIN KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2005-06-09 | — | — | WO | disclosed |
| US-6897231-B2 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, INC. (US) | 2005-05-24 | — | — | US | disclosed |
| US-20050107457-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | SINGNAL PHARMACEUTICALS, INC. | 2005-05-19 | — | — | US | disclosed |
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2005-01-13 | — | — | US | disclosed |
| WO-2004094388-A2 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2004-11-04 | — | — | WO | disclosed |
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC | 2004-07-01 | — | — | US | disclosed |
| US-20040077877-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, INC. | 2004-04-22 | — | — | US | disclosed |
| EP-1313711-A2 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | SIGNAL PHARMACEUTICALS, INC. (US) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002010137-A9 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | SIGNAL PHARM INC (US) | 2003-02-06 | — | — | WO | disclosed |
| US-20020103229-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, LLC | 2002-08-01 | — | — | US | disclosed |
| WO-2002010137-A2 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | SIGNAL PHARMACEUTICALS, INC. (US) | 2002-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | MAPK1, MAP3K1, MAPKAPK2 | RXRA 794/4885RXRB 1055/4885RXRG 988/4885 |
| US-20040077877-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | MAP3K7, MAP3K1, MAP3K8 | RXRA 988/4885RXRB 1070/4885RXRG 917/4885 |
| US-20070060616-A1 | Methods for treating, preventing and managing chronic lymphocytic leukemia with indazole compounds | BCL9, MCL1, INMT | RXRA 1705/4885RXRB 1847/4885RXRG 1659/4885 |
| US-20050107457-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | MAP3K7, MAP3K1, MAP3K8 | RXRA 1218/4885RXRB 1252/4885RXRG 1030/4885 |
| US-20020103229-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | MAP3K7, MAP3K1, MAP3K8 | RXRA 988/4885RXRB 1070/4885RXRG 917/4885 |
| US-20090099178-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF | WNT3, WNT3A, WNK3 | RXRA 2265/4885RXRB 2226/4885RXRG 2156/4885 |
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | GPR119, JAK3, IGF1R | RXRA 1788/4885RXRB 1583/4885RXRG 1709/4885 |
| US-20060004043-A1 | Indazole compounds and methods of use thereof | WNT3, WNT3A, WNK3 | RXRA 2170/4885RXRB 2113/4885RXRG 2042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.